Stock Research for ARWR

ARWR
Current Price

$5.7900


Latest Update: 2018-02-23 16:00:00

High
$ 5.8000
Low
$ 5.7850
Close
$ 5.8000
Volume
28049
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ARWR Stock Chart & Research Data

The ARWR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARWR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARWR Due diligence Resources & Stock Charts

The ARWR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARWR Detailed Price Forecast - CNN Money CNN View ARWR Detailed Summary - Google Finance
Yahoo View ARWR Detailed Summary - Yahoo! Finance Zacks View ARWR Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ARWR Trends & Analysis - Trade-Ideas Barrons View ARWR Major Holders - Barrons
NASDAQ View ARWR Call Transcripts - NASDAQ Seeking View ARWR Breaking News & Analysis - Seeking Alpha
Spotlight View ARWR Annual Report - CompanySpotlight.com OTC Report View ARWR OTC Short Report - OTCShortReport.com
TradeKing View ARWR Fundamentals - TradeKing Charts View ARWR SEC Filings - Bar Chart
WSJ View Historical Prices for ARWR - The WSJ Morningstar View Performance/Total Return for ARWR - Morningstar
MarketWatch View the Analyst Estimates for ARWR - MarketWatch CNBC View the Earnings History for ARWR - CNBC
StockMarketWatch View the ARWR Earnings - StockMarketWatch MacroAxis View ARWR Buy or Sell Recommendations - MacroAxis
Bullish View the ARWR Bullish Patterns - American Bulls Short Pains View ARWR Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ARWR Stock Mentions - StockTwits PennyStocks View ARWR Stock Mentions - PennyStockTweets
Twitter View ARWR Stock Mentions - Twitter Invest Hub View ARWR Investment Forum News - Investor Hub
Yahoo View ARWR Stock Mentions - Yahoo! Message Board Seeking Alpha View ARWR Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ARWR - SECform4.com Insider Cow View Insider Transactions for ARWR - Insider Cow
CNBC View ARWR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARWR - OTC Markets
Yahoo View Insider Transactions for ARWR - Yahoo! Finance NASDAQ View Institutional Holdings for ARWR - NASDAQ


Stock Charts

FinViz View ARWR Stock Insight & Charts - FinViz.com StockCharts View ARWR Investment Charts - StockCharts.com
BarChart View ARWR Stock Overview & Charts - BarChart Trading View View ARWR User Generated Charts - Trading View


Latest Financial News for ARWR

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Posted on Thursday February 22, 2018

Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.


Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
Posted on Thursday February 15, 2018

Arrowhead Pharmaceuticals Inc. today announced the United States Food and Drug Administration has granted orphan drug designation to ARO-AAT, Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.


Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Posted on Thursday February 15, 2018

Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection.


Arrowhead Research reports 1Q loss
Posted on Friday February 09, 2018

The Pasadena, California-based company said it had a loss of 18 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...


Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
Business Wire (press release) - Feb 15, 2018
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to ARO-AAT, Arrowhead's second-generation investigational medicine ...

B. Riley Equities Analysts Boost Earnings Estimates for Arrowhead ...
StockNewsTimes - 6 hours ago
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) - Stock analysts at B. Riley lifted their Q2 2018 earnings estimates for Arrowhead Pharmaceuticals in a report issued on Monday, Zacks Investment Research reports.
Arrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study ... - StreetInsider.com
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Has Decline in Shorts - Frisco Fastball

Arrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AAT
StreetInsider.com - Feb 15, 2018
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to ARO-AAT, Arrowhead's second-generation investigational medicine for the treatment of a rare ...
How Insiders and Institutions are Trading Arrowhead Pharmaceuticals, Inc. (ARWR) - StockNewsGazette

Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q1 2018 Results ...
Seeking Alpha - Feb 10, 2018
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2018 Earnings Conference Call February 9, 2018 4:30 PM ET. Executives. Vincent Anzalone - VP, Head of Investor Relations.
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Arrowhead ... - StockNewsTimes

Enter a stock symbol to view the stock details.